Fine specificity and cross-reactions of monoclonal antibodies to group B streptococcal capsular polysaccharide type III

Vaccine

Volumn 30, Issue 32, 2012, Pages 4849-4858

  Pincus, Seth H ^a,b   Moran, Emily ^a   Maresh, Grace ^a   Jennings, Harold J ^c   Pritchard, David G ^d   Egan, Marianne L ^e   Blixt, Ola ^f  

^a CHILDREN S HOSPITAL   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Capsular polysaccharide; Carbohydrate array; Cross reaction; Fine specificity; Group B streptococci; Monoclonal Ab

Indexed keywords

CARBOHYDRATE; GANGLIOSIDE GD3; GANGLIOSIDE GT3; MONOCLONAL ANTIBODY; POLYSACCHARIDE; SIALIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CARBOHYDRATE ANALYSIS; CELL SURFACE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; LEUKOCYTE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS AGALACTIAE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BACTERIAL CAPSULES; CARBOHYDRATES; CELL LINE; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GANGLIOSIDES; HUMANS; LACTOSYLCERAMIDES; LEUKOCYTES, MONONUCLEAR; MICE; POLYSACCHARIDES, BACTERIAL;

EID: 84862535109     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.006     Document Type: Article

References (53)

1. Prevention CfDCa Prevention of perinatal group B streptococcal disease: a public health perspective. Morbidity and Mortality Weekly Report 1996, 45:1-24.
2. Baker C.J., Kasper D.L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. New Eng J Med 1976, 294:753-756.
3. Baker C.J., Kaspar D.L. Immunologic investigation of infants with septicemia or meningitis due to group B streptococcus. J Infect Dis 1977, 136:598-604.
4. Wessels M.R., Paoletti L.C., Kasper D.L., DiFabio J.L., Michon F., Holme K., et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 1990, 86:1428-1433.
5. Madoff L.C., Paoletti L.C., Tai J.Y., Kasper D.L. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest 1994, 94:286-292.
6. Paoletti L.C., Wessels M.R., Rodewald A.K., Shroff A.A., Jennings H.J., Kasper D.L. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Inf Immun 1994, 62:3236-3243.
7. Baker C.J., Rench M.A., Edwards M.S., Carpenter R.J., Hays B.M., Kasper D.L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. New Eng J Med 1988, 319:1180-1185.
8. Kasper D.L., Paoletti L.C., Wessels M.R., Guttormsen H-K., Carey V.J., Jennings H.J., et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996, 98:2308-2314.
9. Van Dyke M.K., Phares C.R., Lynfield R., Thomas A.R., Arnold K.E., Craig A.S., et al. Evaluation of universal antenatal screening for group B streptococcus. N Eng J Med 2009, 360(Jun (25)):2626-2636.
10. Lancefield R.C. A serologic differentiation of specific types of bovine hemolytic streptococci (group B). J Exp Med 1934, 59:441-458.
11. Lancefield R.C., McCarty M., Everly W.N. Multiple mouse-protective antibodies directed against group B streptococci. J Exp Med 1975, 142:165-179.
12. Lancefield R.C., Freimer E.H. Type specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 1966, 64:191-199.
13. Lancefield R.C. Two serological types of group B hemolytic streptococci with related, but not identical, type specific substances. J Exp Med 1938, 67:25-40.
14. Pincus S.H., Shigeoka A.O., Moe A.A., Ewing L.P., Hill H.R. Protective efficacy of IgM monoclonal antibodies in experimental group B streptococcal infection is a function of antibody avidity. J Immunol 1988, 140:2779-2785.
15. Shigeoka A.O., Pincus S.H., Rote N.S., Pritchard D.G., Santos J.I., Hill H.R. Monoclonal antibody preparations for immunotherapy of experimental GBS infection. Antibiot Chemother 1985, 35:254-266.
16. Shigeoka A.O., Pincus S.H., Rote N.S., Hill H.R. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus. J Infect Dis 1984, 149:363-372.
17. Egan M.L., Pritchard D.G., Dillon H.C., Gray B.M. Protection of mice from infection with type III group B streptococcus using monoclonal antibodies. J Exp Med 1983, 158:1006-1020.
18. Wessels M.R., Rubens C.E., Benedi J.V., Kasper D.L. Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci USA 1989, 86:8983-8987.
19. Pincus S.H., Cole R.L., Wessels M.R., Corwin M.D., Kamanga-Sollo E., Hayes S.F., et al. Group B streptococcal opacity variants. J Bacteriol 1992, 174:3739-3749.
20. Pincus S.H., Cole R.L., Kamanga-Sollo E., Fischer S.H. Interaction of group B streptococcal opacity variants with the host defense system. Infect Immun 1993, 61:3761-3768.
21. Edwards M.S., Kasper D.L., Jennings H.J., Baker C.J., Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol 1982, 128:1278-1283.
22. Marques M.B., Kasper D.L., Pangburn M.K., Wessels M.R. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Inf Immun 1992, 60:3986-3993.
23. Campbell J.R., Baker C.J., Edwards M.S. Deposition and degradation of C3 on type III group B streptococci. Inf Immun 1991, 59:1978-1983.
24. Paulson J.C., Blixt O., Collins B.E. Sweet spots in functional glycomics. Nat Chem Biol 2006, 2:238-248.
25. Blixt O., Head S., Mondala T., Scanlan C., Huflejt M.E., Alvarez R., et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA 2004, 101:17033-17038.
26. Pukel C.S., Lloyd K.O., Travassos L.R., Dippold W.G., Oettgen H.F., Old L.J. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 1982, 155(April (4)):1133-1147.
27. Constantine-Paton M., Blum A.S., Mendez-Otero R., Barnstable C.J. A cell surface molecule distributed in a dorsoventral gradient in the perinatal rat retina. Nature 1986, 324(January (6096)):459-462.
28. Cheresh D.A., Harper J.R., Schulz G., Reisfeld R.A. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 1984, 81(September (18)):5767-5771.
29. Farrer R.G., Quarles R.H. GT3 and its O-acetylated derivative are the principal A2B5-reactive gangliosides in cultured O2A lineage cells and are down-regulated along with O-acetyl GD3 during differentiation to oligodendrocytes. J Neurosci Res 1999, 57:371-380.
30. Wang H-W., Muguira M., Liu W-D., Zhang T., Chen C., Aucoin R., et al. Identification of an INSM1-binding site in the insulin promoter: negative regulation of the insulin gene transcription. J Endocrinol 2008, 198(July (1)):29-39.
31. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 1988, 62:3779-3788.
32. Pincus S.H., Fang H., Wilkinson R.A., Marcotte T.K., Robinson J.E., Olson W.C. In vivo efficacy of anti-gp41, but not anti-gp120, immunotoxins in a mouse model of HIV infection. J Immunol 2003, 170:2236-2241.
33. Wessels M.R., Pozsgay V., Kasper D.L., Jennings H.J. Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem 1987, 262:8262-8267.
34. Shigeoka A.O., Pincus S.H., Rote N.S., Hill H.R. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B streptococccus. J Infect Dis 1984, 149:363.
35. Zou W., Mackenzie R., Thérien L., Hirama T., Yang Q., Gidney M.A., et al. Conformational epitope of the type III group B streptococcus capsular polysaccharide. J Immunol 1999, 163(July (2)):820-825.
36. Farrer R.G., Quarles R.H. Expression of sulfated gangliosides in the central nervous system. J Neurochem 1997, 68(February (2)):878-881.
37. Irwin L.N., Michael D.B., Irwin C.C. Ganglioside patterns of fetal rat and mouse brain. J Neurochem 1980, 34(Jun (6)):1527-1530.
38. Schlosshauer B., Blum A.S., Mendez-Otero R., Barnstable C.J., Constantine-Paton M. Developmental regulation of ganglioside antigens recognized by the JONES antibody. J Neurosci 1988, 8(February (2)):580-592.
39. Gillard B.K., Thomas J.W., Nell L.J., Marcus D.M. Antibodies against ganglioside GT3 in the sera of patients with type I diabetes mellitus. J Immunol 1989, 142(June (11)):3826-3832.
40. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987, 138(June (12)):4402-4407.
41. Finne J., Finne U., Deagostini-Bazin H., Goridis C. Occurrence of alpha 2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun 1983, 112(April (2)):482-487.
42. Paoletti L.C., Madoff L.C., Kasper D.L. Surface structures of group B streptococcus important in human immunity. Gram-positive pathogens 2000, 137-153. ASM Press, Washington, DC. V.A. Fischetti, R.P. Novick, J.J. Ferretti, D.A. Prtnoy, J.I. Rood (Eds.).
43. Brisson J-R., Uhrinova S., Woods R.J., van der Zwan M., Jarrell H.C., Paoletti L.C., et al. NMR and molecular dynamics studies of the conformational epitope of the type III group B streptococcus type III capsular polysaccharide. Biochemistry 1997, 36:3278-3292.
44. Safari D., Dekker H.A.T., Rijkers G.T., van der Ende A., Kamerling J.P., Snippe H. The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal-backbone epitope. Glycoconj J 2011, 28(December (8-9)):557-562.
45. Marques M.B., Kasper D.L., Shroff A.A., Michon F., Jennings H.J., Wessels M.R. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun 1994, 62:1593.
46. Baker C.J., Rench M.A., Kasper D.L. Response to type III polysaccharide in women whose infants have had invasive group B streptococcal infection. New Eng J Med 1990, 322:1857-1860.
47. Pon R.A., Lussier M., Yang Q.L., Jennings H.J. N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitides. J Exp Med 1997, 185(June (11)):1929-1938.
48. Kaida K., Ariga T., Yu R.K. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders-a review. Glycobiology 2009, 19(July (7)):676-692.
49. Yu R.K., Usuki S., Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases. Inf Immun 2006, 74(December (12)):6517-6527.
50. Schrag S.J., Zywicki S., Farley M.M., Reingold A.L., Harrison L.H., Lefkowitz L.B., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. New Eng J Med 2000, 342:15-20.
51. Paoletti L.C., Wessels M.R., Rodewalk A.K., Shroff A.A., Jennings H.J., Kasper D.L. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1994, 62:3236.
52. Li R-K., Cutler J. Chemical definition of an epitope/adhesin on Candida albicans. J Biol Chem 1993, 268:18293-18299.
53. Nano F.E., Caldwell H.D. Expression of the chlamydial genus-specific lipopolysaccharide epitope in Escherichia coli. Science 1985, 228:742-744.